合作客戶/
拜耳公司 |
同濟(jì)大學(xué) |
聯(lián)合大學(xué) |
美國(guó)保潔 |
美國(guó)強(qiáng)生 |
瑞士羅氏 |
相關(guān)新聞Info
-
> 某種物體表面張力系數(shù)為零會(huì)發(fā)生什么現(xiàn)象？
> 嵌段聚醚型破乳劑AE-1和SP169與模擬油的界面張力測(cè)定
> 平面流動(dòng)皂膜表面張力系數(shù)、厚度和流動(dòng)速度實(shí)驗(yàn)裝置及測(cè)量方法（二）
> 放心喝！張家界6處地下水水源地水質(zhì)達(dá)標(biāo)
> 純水表面張力與液膜拉伸形變量關(guān)系|純水表面張力測(cè)試數(shù)據(jù)
> 耐擦刮無(wú)膠消光膜制備方法、高表面張力與收解卷順暢性的平衡（二）
> ?平衡/動(dòng)態(tài)表面張力測(cè)定：煤基C10～13MADS VS2A1
> Langmuir槽法研究不同電性Gemini表面活性劑對(duì)界面吸附膜性質(zhì)的影響（二）
> 0.01mg是什么精度的天平？超微量天平的稱重范圍
> 傳統(tǒng)的表面張力儀的功能簡(jiǎn)介
推薦新聞Info
-
> 添加表面活性劑抑制瓦斯解吸效果及機(jī)理分析
> 常見(jiàn)表面活性劑分類、性質(zhì)、水溶液潤(rùn)濕性、與表面張力間的關(guān)系
> ?基于LB膜技術(shù)的仿生膠原膜模塊化組裝方法
> 明確巖心孔喉大小及分布，構(gòu)建低滲透油藏CO2驅(qū)開(kāi)發(fā)全過(guò)程動(dòng)態(tài)預(yù)測(cè)模型（二）
> 明確巖心孔喉大小及分布，構(gòu)建低滲透油藏CO2驅(qū)開(kāi)發(fā)全過(guò)程動(dòng)態(tài)預(yù)測(cè)模型（一）
> ?序列結(jié)構(gòu)決定性能：深度解析陽(yáng)離子聚丙烯酸酯浮選劑的構(gòu)效關(guān)系及表征關(guān)鍵
> 酯化度與分子質(zhì)量對(duì)果膠乳化性能、聚集體結(jié)構(gòu)、界面性質(zhì)的影響規(guī)律（三）
> 酯化度與分子質(zhì)量對(duì)果膠乳化性能、聚集體結(jié)構(gòu)、界面性質(zhì)的影響規(guī)律（二）
> 酯化度與分子質(zhì)量對(duì)果膠乳化性能、聚集體結(jié)構(gòu)、界面性質(zhì)的影響規(guī)律（一）
> 反離子鹽KBr濃度對(duì)酰胺基陽(yáng)離子Gemini表面活性劑的表/界面活性的影響（三）
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——結(jié)論、工具書(shū)類！
來(lái)源：上海謂載 瀏覽 1801 次 發(fā)布時(shí)間:2021-11-26
結(jié)論
胃腸道pH值和緩沖容量的種間差異是重要的考慮因素，尤其是對(duì)胃腸道給藥的pHresponsive配方和可電離藥物。 因此，兔子和豬的空腸、回腸和近端結(jié)腸具有相對(duì)較高的緩沖容量，而豬遠(yuǎn)端結(jié)腸具有較低的緩沖容量是非常重要的考慮因素。 與人相比，大鼠、兔和豬的近端小腸和升結(jié)腸的液體的滲透壓和表面張力也較高。 胃腸道特征的這些差異導(dǎo)致潑尼松龍?jiān)诖笫篌w內(nèi)的溶解度較高（近端結(jié)腸除外），而潑尼松龍?jiān)谪i和兔體內(nèi)的溶解度與人類相當(dāng)。 因此，如果在大鼠的體液中測(cè)量，中性化合物潑尼松龍的溶解度可能被高估。 另一方面，可電離藥物美沙拉秦在兔和豬體內(nèi)的溶解度在小腸中部高于人，在結(jié)腸中低于人，僅在小腸遠(yuǎn)端與人相當(dāng)。 胃腸道環(huán)境的差異，如pH值、緩沖容量、滲透壓和表面張力，導(dǎo)致藥物溶解度的差異。 在兔子和豬中，美沙拉秦的溶解度在沿胃腸道向下移動(dòng)時(shí)發(fā)生顯著變化，這在很大程度上受管腔液的pH值和滲透壓的影響。
工具書(shū)類
1. Flaisher-Grinberg S et al. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010; 24: 437–438.
2. Insel TR. From animal models to model animals. Biol Psychiatry 2007; 62: 1337–1339.
3. Hannah-Poquette C et al. Modeling mania: further validation for Black Swiss mice as model animals. Behav Brain Res 2011; 223: 222–226.
4. Calabrese EJ. Gastrointestinal and dermal absorption – interspecies differences. Drug Metab Rev 1984; 15: 1013–1032.
5. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory-animals. Biopharm Drug Dispos 1995; 16: 351–380.
6. McConnell EL et al. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 2008; 60: 63–70.
7. Ward FW, Coates ME. Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting. Lab Anim 1987; 21: 216–222.
8. Smith HW. Observations on the Flora of the alimentary tract of animals and factors affecting its composition. J Pathol Bacteriol 1965; 89: 95–122.
9. Clarysse S et al. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 2009; 98: 1177–1192.
10. Kalantzi L et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23: 165–176.
11. Fadda HM et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm 2010; 7: 1527– 1532.
12. Merchant HA et al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci 2011; 42: 3–10.
13. ToxNet. Mesalamine: Toxicology data network (ToxNet). US National Library of Medicine, CASRN: 89-57-6. 2014. (http://toxnet.nlm.nih.gov/cgi-bin/sis/ search2/r?dbs+hsdb:@term+@rn+@ rel+89-57-6, last accessed 25th June 2014).
14. Machatha SG, Yalkowsky SH. Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int J Pharm 2005; 294: 185–192.
15. McConnell EL et al. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008; 364: 213–226.
16. Mudie DM et al. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010; 7: 1388– 1405.
17. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res 1993; 10: 1285–1290.
18. Perez de la Cruz Moreno M et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079–1089. 19. Diakidou A et al. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res 2009; 26: 2141–2151.
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——摘要、介紹
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——材料和方法